Date | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) |
---|
CEO | Hyo Keun Lee |
IPO Date | July 16, 2021 |
Location | South Korea |
Headquarters | 16 Deokyeong-daero |
Employees | 576 |
Sector | Health Care |
Industries |
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Past 5 years
USD 14.39
USD 125.83
USD 17.39
USD 75.63
USD 33.55
StockViz Staff
January 15, 2025
Any question? Send us an email